Key Milestone in GBA-PD Therapy Development Ach...

By João L. Carapinha

May 26, 2026

Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to...
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen
Emergence of AI Healthcare Policy Amidst Fragmentation and Governance Challenges
Hepcludex HDV Approval: A Breakthrough in Chronic Hepatitis Delta Treatment
CHMP Recommendations 2026: New Approvals and Implications for Health Economics
Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report
Novartis Oncology Advancements: Key Trial Findings and Market Implications
EUDAMED Implementation 2026: Key Changes and National Adaptations
Baxfendy Hypertension Treatment: FDA Approves First-in-Class Aldosterone Synt...
TrumpRx.gov Expansion: Enhancing Medication Price Transparency and Competition
Trastuzumab-Deruxtecan Reimbursement: A Careful Evaluation of Cost-Effectiven...
Portugal Health Spending 2025 Reaches Record €4.417 Billion Amid Rising Demand